0.00Open0.04Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-85.06%PremiumSep 20, 2024Expiry Date14.50Intrinsic Value100Multiplier-7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma425.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cartesian Therapeutics Stock Discussion
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment
Dow Jones· just
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Murat Kalayoglu(19.9%),Seven One Eight Three Four Irrevocable Trust(17.1%), etc.
SEC announcement
13 mins ago
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals...
No comment yet